Dexcom will present the full data from several studies at the Advanced Technologies and Treatments for Diabetes conference, ...

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the 47th Annual Raymond James Institutional Investors Conference on ...

Jacob Steven Leach, DexCom, Inc.'s President and CEO who will summarize our recent highlights and ongoing strategic initiatives. Followed by a financial review and outlook from Jereme M. Sylvain, our ...

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the 47th Annual Raymond James Institutional Investors Conference on Monday, March 2, 2026. The live ...

Dexcom has achieved revenues of $4.66bn in 2025 and beat analysts’ consensus for Q4 performance amid a strong demand for its continuous glucose monitoring (CGM) systems. Yet its 2026 outlook was lower ...

Analysts feared the advent of GLP-1 medications would harm DexCom's blood glucose monitoring devices. However, as its turns out, DexCom's devices are being prescribed together with GLP-1s. The company ...

The Stelo is available to anyone who wants to monitor their blood glucose, no prescription needed. But as an active adult without diabetes, are these extra data points worth $99 per month?

SAN DIEGO - DexCom, Inc. (NASDAQ:DXCM) announced the appointment of Rick Osterloh to its Board of Directors, effective today, according to a press release statement. Osterloh serves as Senior Vice ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Rick Osterloh to its Board of Directors, effective February 26, 2026. Mr. Osterloh is a highly ...

DexCom Inc. reports fourth-quarter earnings Thursday after the market close, with investors eager to gauge whether the continuous glucose monitoring leader can defend its premium market position ...

We have excluded third-party attorney’s fees, costs, and expenses incurred by Dexcom exclusively in connection with Dexcom’s patent infringement litigation against Abbott Diabetes Care, Inc., as ...

Dexcom Inc. (NASDAQ:DXCM) released its fourth quarter 2025 earnings presentation on February 12, 2026, highlighting strong financial performance despite market challenges in the continuous glucose ...